Rigel's fostamatinib misses primary endpoint in Phase 3 COVID-19 trial; p=0.0603

RIGEL PHARMACEUTICALS INC

FOCUS Phase 3 trial of fostamatinib in high-risk hospitalized COVID-19 patients did not meet primary endpoint for days on oxygen (p=0.0603).
Mean days on oxygen were 6.9 for fostamatinib vs 9.0 for placebo; mortality 4 vs 8 deaths (50% reduction, p=0.4521).
All prespecified secondary endpoints numerically favored fostamatinib, including ordinal scale change to Day 15 (-2.4 vs -1.9, p=0.0428).
Safety profile consistent with prior experience; no new safety issues; study supported by U.S. Department of Defense.
Company evaluating next steps in collaboration with partner, U.S. Department of Defense.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.